| Literature DB >> 29116293 |
Michelly Cristina Montenote1, Vithor Zuccaro Wajsman1, Yoichi Takaki Konno1, Paulo César Ferreira2, Regildo Márcio Gonçalves Silva2, Altino Luiz Silva Therezo3, Luciana Pereira Silva4, Luciamáre Perinetti Alves Martins1.
Abstract
Considering the widespread popular use of Morus nigra and the amount of scientific information on its antioxidant and anti-inflammatory activity, the effectiveness of this phytotherapeutic compound in the parasitemia progression during the acute phase of Chagas disease and its role in the development of the inflammatory process as well as its effects on the oxidative damage in the chronic phase of infection were evaluated. Thus, 96 male Swiss mice were randomly divided into eight groups, four groups were uninfected controls, and four groups were intraperitoneally infected with 5.0 x 104 blood trypomastigotes forms of T. cruzi QM2 strain. Four batches composed of one uninfected and one infected group were respectively treated with 70% alcohol solution and 25 μL, 50 μL and 75 μL of the phytotherapeutic compound. Levels of antioxidant elements (TBARS, FRAP, GSH and Sulfhydryl groups) were measured in plasma samples. The phytotherapeutic compound's antioxidant activity was measured by polyphenol and total flavonoid quantification, DPPH, NO, and FRAP method. Our results showed that the vehicle influenced some of the results that may have physiological relevance in Chagas disease. However, an important action of M. nigra tincture was observed in the progression of Chagas disease, since our results demonstrated a reduction in parasitemia of treated groups when compared to controls, especially in the group receiving 25 µL. However, in the chronic phase, the 50-µL dosage presented a better activity on some antioxidant defenses and minimized the tissue inflammatory process. Results indicated an important action of M. nigra tincture on the Chagas disease progression.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29116293 PMCID: PMC5679685 DOI: 10.1590/S1678-9946201759073
Source DB: PubMed Journal: Rev Inst Med Trop Sao Paulo ISSN: 0036-4665 Impact factor: 1.846
Figure 1Free radical scavenging activity DPPH in M. nigra - phytotherapy compound
Free radical DPPH and nitric oxide (NO) scavenging activity, polyphenols, total flavonoid and FRAP test in M. nigra - phytotherapy compound
| Total Polyphenolsa | Total Flavonoidsb | FRAPc | DPPH EC50% (µl/mL) | Nitric Oxided Control: 10.11e | |
|---|---|---|---|---|---|
| Phytomedicine | 261.66 | 361.83 | 32.09 | 72.2 | 13.64 |
aµg of gallic acid quivalent/mL of the phytomedicine, bµg of rutine equivalent/mL of phytomedicine. cµM trolox equivalent/g of phytomedicine. dµM/mL of nitrite concentration formed by the antioxidant capacity of NO capture. e µM/mL of gallic acid.
Figure 2Parasitemia curve by logarithmic mean of the number of trypomastigotes/5 μL of blood in the different experimental groups during the acute phase from the 7th to the 60th day of infection
Number of animals that survived in each group during the chronic phase of infection
| Group | Number of animals | |
|---|---|---|
| Uninfected | Control(-) | 11 |
| 25μL(-) | 11 | |
| 50μL(-) | 11 | |
| 75μL(-) | 9 | |
| Infected | Control(+) | 8 |
| 25μL(+) | 10 | |
| 50μL(+) | 8 | |
| 75μL(+) | 12 |
Figure 3FRAP results in different concentrations of the phytotherapy compound of M. nigra expressed in mean and standard deviation. Averages followed by the same designation do not differ from one another by the Dunn test at the 5% probability level
Figure 4TBARS results in different concentrations of the phytotherapy compound of M. nigra expressed in mean and standard deviation. Averages followed by the same designation do not differ from one another by the Dunn test at the 5% probability level
Figure 5GSH results in different concentrations of the phytotherapy compound of M. nigra expressed in mean and standard deviation. Averages followed by the same designation do not differ from one another by the Dunn test at the 5% probability level
Figure 6Sulfhydryl groups results in different concentrations of the phytotherapy compound of M. nigra expressed in mean and standard deviation. Averages followed by the same designation do not differ from one another by the Dunn test at the 5% probability level
Histopathological analysis performed in skeletal muscle, cardiac muscle and colon during the chronic phase of infection, in mice experimentally infected by Trypanosoma cruzi QM2 strain and treated with alcoholic solution (control), 25, 50 and 75 μL of Morus nigra phytotherapy compound.”%” indicates the percentage of mice with inflammation or necrosis in each group, and ( ) * indicates the absolute number of animals in each group
| Groups | Histological Analysis | Skeletal muscle | Cardiac muscle | Colon | |
|---|---|---|---|---|---|
| C(+) | Inflammation %(8)* | + | 50.0 (4) | 87.5 (7) | 62.5 (5) |
| ++ | 37.5 (3) | --- | --- | ||
| +++ | --- | --- | --- | ||
| Amastigote %(8)* | + | --- | 25.0 (2) | 12.5 (1) | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| Necrosis %(8)* | + | 25.0 (2) | --- | --- | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| 25(+) | Inflammation %(10)* | + | 90.0 (9) | 40.0 (4) | 10.0 (1) |
| ++ | 10.0 (1) | 40.0 (4) | --- | ||
| +++ | --- | --- | --- | ||
| Amastigote %(10)* | + | 8.3 (1) | --- | 30.0 (3) | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| Necrosis %(10)* | + | 20.0 (2) | --- | --- | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| 50(+) | Inflammation %(8)* | + | 62.5 (5) | 25.0 (2) | 37.5 (3) |
| ++ | 12.5 (1) | 12.5 (1) | --- | ||
| +++ | --- | --- | --- | ||
| Amastigote % (8)* | + | 12.5 (1) | --- | --- | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| Necrosis %(8)* | + | 12.5 (1) | --- | --- | |
| ++ | 12.5 (1) | --- | --- | ||
| +++ | --- | --- | --- | ||
| 75(+) | Inflammation %(12)* | + | 83.3 (10) | 58.3 (7) | 24.9 (3) |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| Amastigote %(12)* | + | 8.3 (1) | --- | --- | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- | ||
| Necrosis %(12)* | + | 16.6 (2) | --- | --- | |
| ++ | --- | --- | --- | ||
| +++ | --- | --- | --- |
Figure 7– Histological preparations of infected animals stained with hematoxylin-eosin: A) presence of inflammation in the control animal’s colon; B) presence of amastigotes nests in the skeletal musculature of animals from the 50 μL group; C) myocardial necrosis in a sample from a 25 μL group animal